Your institution may have access to this item. Find your institution then sign in to continue.
Title
Question-and-Answer Forum.
Abstract
An interview with physicians Kris V. Kowdley, Ira M. Jacobson and Paul Y. Kwo about ribavirin (RBV) dose reduction in anemia management is presented. They tackle whether preemptive RBV dose reduction is an option for preventing anemia. They cite the marker for sensitivity to RBV and subsequent anemia. They also discuss whether the use of lead-in therapy with RBV/pegIFN-α is useful in patients at high risk for anemia.